Abstract
Ocular diseases such as glaucoma and macular degeneration can greatly impact the quality of patients’ lives, with the possibility of loss of vision. The development of orally available drugs that can reach the posterior segment of the eye is hampered by the anatomy of the eye. In this chapter, we describe methods for obtaining and analyzing retina and associated optic tract structures for drug levels. These techniques can be used in drug development paradigms as well as for regulatory approval processes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Molokhia SA, Thomas SC, Garff KJ, Mandell KJ, Wirostko BM (2013) Anterior eye segment drug delivery systems: current treatments and future challenges. J Ocul Pharm Therap 29(2):92–105
Alqawlaq S, Huzil JT, Ivanova MV, Foldvari M (2012) Challenges in neuroprotective nanomedicine development: progress towards noninvasive gene therapy of glaucoma. Nanomedicine (Lond) 7(7):1067–1083
Rawas-Qalaji M, Williams CA (2012) Advances in ocular drug delivery. Curr Eye Res 37(5):345–356
Thrimawithana TR, Young S, Bunt CR, Green C, Alany RG (2011) Drug delivery to the posterior segment of the eye. Drug Discov Today 16(5–6):270–277
Zhang K, Zhang L, Weinreb RN (2012) Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma. Nat Rev Drug Discov 11(7):541–559
Clark AF, Yorio T (2003) Ophthalmic drug discovery. Nat Rev Drug Discov 2(6):448–459
Hosoya K, Tachikawa M (2012) The inner blood-retinal barrier: molecular structure and transport biology. Adv Exp Med Biol 763:85–104
Hosoya K, Yamamoto A, Akanuma S, Tachikawa M (2010) Lipophilicity and transporter influence on blood-retinal barrier permeability: a comparison with blood-brain barrier permeability. Pharm Res 27(12):2715–2724
Runkle EA, Antonetti DA (2011) The blood-retinal barrier: structure and functional significance. Methods Mol Biol 686:133–148
Simo R, Villarroel M, Corraliza L, Hernandez C, Garcia-Ramirez M (2010) The retinal pigment epithelium: something more than a constituent of the blood-retinal barrier—implications for the pathogenesis of diabetic retinopathy. J Biomed Biotechnol 201:190724
Stewart PA, Tuor UI (1994) Blood-eye barriers in the rat: correlation of ultrastructure with function. J Comp Neurol 340(4):566–576
Kubo Y, Kusagawa Y, Tachikawa M, Akanuma S, Hosoya K (2013) Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier. Pharm Res 30(3):847–856
Hosoya K, Tachikawa M (2009) Inner blood-retinal barrier transporters: role of retinal drug delivery. Pharm Res 26(9):2055–2065
Kubo Y, Shimizu Y, Kusagawa Y, Akanuma SI, Hosoya KI (2013) Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter. J Pharm Sci 102(9):3332–3342
Kubo Y, Hosoya K (2012) Inner blood-retinal barrier transporters: relevance to diabetic retinopathy. In: Ols MS (ed) Diabetic retinopathy. InTech, Croatia, pp 91–108
Acknowledgment
This work was funded in part by the Bloomberg Foundation, Youngstown, OH.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this protocol
Cite this protocol
Van der Schyf, C.J., Crish, S.D., Crish, C., Inman, D., Geldenhuys, W.J. (2013). ADME and Ocular Therapeutics: Retina. In: Gilger, B. (eds) Ocular Pharmacology and Toxicology. Methods in Pharmacology and Toxicology. Humana Press, Totowa, NJ. https://doi.org/10.1007/7653_2013_12
Download citation
DOI: https://doi.org/10.1007/7653_2013_12
Published:
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-62703-744-0
Online ISBN: 978-1-62703-745-7
eBook Packages: Springer Protocols